Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

Neurology

Volumn 76, Issue 8, 2011, Pages 693-700

  Garvey, L ^a,b   Winston, A ^a,b   Walsh, J ^b   Post, F ^c   Porter, K ^d   Gazzard, B ^e   Fisher, M ^f   Leen, C ^g   Pillay, D ^h   Hill, T ⁱ   Johnson, M ^j   Gilson, R ⁱ   Anderson, J ^k   Easterbrook, P ^c   Bansi, L ⁱ   Orkin, C ^l   Ainsworth, J ^m   Palfreeman, A ⁿ   Gompels, M ^o   Phillips, A N ⁱ   Sabin, C A ⁱ   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UK   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^l ROYAL LONDON HOSPITAL   (United Kingdom)

^m NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

ⁿ LEICESTER ROYAL INFIRMARY   (United Kingdom)

^o SOUTHMEAD HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; CRYPTOCOCCAL MENINGITIS; DRUG PENETRATION; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; TOXOPLASMOSIS;

EID: 79952020252     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820d8b0b     Document Type: Article

References (17)

1. Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event: The AIDS in Europe Study Group. Int J Epidemiol 1997;26:400-407. (Pubitemid 27190313)
2. Fong IW, Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 1995;20:1305-1310.
3. Grabar S, Lanoy E, Allavena C, et al, Clinical Epidemiology Group of the French Hospital Database on HIV. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008;9:246-256.
4. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320-328.
5. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009;82:A99-109.
6. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatmentnaive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010;50:920-929.
7. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
8. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73:342-348.
9. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009;52:56-63.
10. Patel K, Ming X, Williams PL, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009;23:1893-1901.
11. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359-1366.
12. + patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA. Poster 385.
13. Lanoy E, Bentata M, Guiguet M, et al. Improvement in survival after a neurological-AIDS defining event over time. 11th European AIDS Conference, 2007, Madrid. Abstract PS1/3.
14. Letendre S, FitzSimons C, Ellis R, et al. Correlates of CSF viral loads in 1221 volunteers of the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, San Francisco, CA. Abstract 172.
15. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002;16:1867-1876.
16. Mayeux R, Stern Y, Tang MX, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993;43:176-182. (Pubitemid 23035377)
17. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection: San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997;54:416-424. (Pubitemid 27172861)